Trial Profile

An Open-Label Long-Term Extension Study for Participants From the 299AR301 Felzartamab Study

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 30 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Felzartamab (Primary)
Indications Renal transplant rejection
Focus Adverse reactions; Registrational
Acronyms TRANSCEND LTE
Sponsors Biogen

Most Recent Events

27 Apr 2026 Status changed from not yet recruiting to recruiting.
08 Apr 2026 Planned initiation date changed from 10 Mar 2026 to 6 Apr 2026.
09 Mar 2026 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com